Sign Up
OverviewAPI
The European Commission approves CASGEVY™ (exagamglogene autotemcel) as the first CRISPR/Cas9 gene-edited therapy for severe sickle cell disease and transfusion-dependent beta thalassemia. Vertex leads the development, manufacturing, and commercialization of the therapy under a profit-sharing agreement with CRISPR Therapeutics.

Ask a question